Alpha Advisors’s AbbVie ABBV Stock Holding History

Alpha Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$355K	Buy	1,412 +1	+0.1%	+$215	0.27%	41
2026 Q1	$307K	Buy	1,411 +45	+3%	+$9.98K	0.24%	39
2025 Q4	$312K	Hold	1,366	–	–	0.24%	34
2025 Q3	$316K	Buy	1,366 +17	+1%	+$3.46K	0.24%	34
2025 Q2	$250K	Sell	1,349 -15	-1%	-$2.79K	0.21%	35
2025 Q1	$286K	Buy	1,364 +17	+1%	+$3.31K	0.25%	29
2024 Q4	$239K	Buy	+1,347	New	+$248K	0.25%	34

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Alpha Advisors's ABBV Position: Q2 2026 in Review

Alpha Advisors increased its AbbVie (ABBV) stake by 0.07% in Q2 2026, buying an estimated $215 and bringing the position to 1,412 shares worth $355K. The position accounts for 0.27% of the portfolio, ranked #41.

Alpha Advisors first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,209 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Alpha Advisors held 1,412 shares of AbbVie worth $355K as of Q2 2026.
Alpha Advisors bought 1 AbbVie share in Q2 2026, an estimated $215.
AbbVie made up 0.27% of Alpha Advisors's portfolio in Q2 2026, its #41 holding.
Alpha Advisors first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
4,209 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Alpha Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.